Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma

BACKGROUND: To investigate the maximum tolerated dose (MTD) of apatinib delivered during and after intensity-modulated radiotherapy (IMRT) for unresectable hepatocellular carcinoma (HCC). METHODS: Patients with unresectable HCC who were not eligible for radiofrequency ablation (RFA), transcatheter a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hongzhi, Zhu, Xianggao, Zhao, Yuting, Dong, Dezuo, Li, Lijuan, Cai, Yong, Li, Yongheng, Wang, Weihu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287866/
https://www.ncbi.nlm.nih.gov/pubmed/35840914
http://dx.doi.org/10.1186/s12885-022-09819-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287866/
https://www.ncbi.nlm.nih.gov/pubmed/35840914
http://dx.doi.org/10.1186/s12885-022-09819-3

Ejemplares similares